|
|
 Previous Article | Table of Contents | Next Article 
Effects of recombinant human interleukin-3 in patients with normal
hematopoiesis and in patients with bone marrow failure
A Ganser, A Lindemann, G Seipelt, OG Ottmann, F Herrmann, M Eder, J Frisch, G Schulz, R Mertelsmann and D Hoelzer
Department of Hematology, University of Frankfurt, FRG.
In a phase I/II study, 19 patients with advanced tumors but normal
hematopoiesis and nine patients with bone marrow failure and prolonged
severe cytopenias were treated with recombinant human interleukin-3
(rhIL-3) to assess the toxicity and biological effects of this
multipotential hematopoietic growth factor. Doses ranging from 30
micrograms/m2 to 500 micrograms/m2 were administered as subcutaneous bolus
injection daily for 15 days. A dose-dependent increase in platelet counts
ranging from 1.3-fold at 60 micrograms/m2 to 1.9-fold at 250 micrograms/m2
was induced by rhIL-3 in 15 of 18 evaluable patients with normal
hematopoiesis. An increase in reticulocyte counts was observed in 14
patients. The blood leukocyte counts dose dependently increased 1.4- to
3.0-fold. In patients with bone marrow failure, platelet counts increased
by a mean of sixfold (range, 1.3- fold to 14.3-fold) in five of eight
evaluable patients. Reticulocyte counts increased 4.4-fold in six patients,
and neutrophil counts increased by a mean of 3.1-fold in all eight
patients. Platelet transfusions could be discontinued after treatment with
rhIL-3 in two of three transfusion-dependent patients. Only mild side
effects, mainly fever, headache, and flushing, were observed. These results
indicate that rhIL-3 functions as a multilineage hematopoietin in vivo in
patients with normal bone marrow function and in patients with secondary
bone marrow failure.
Volume 76,
Issue 4,
pp. 666-676,
08/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. A. Velders, R. van Os, H. Hagoort, P. Verzaal, H. F. L. Guiot, I. J. D. Lindley, R. Willemze, G. Opdenakker, and W. E. Fibbe
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization
Blood,
January 1, 2004;
103(1):
340 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Velders, J. F. M. Pruijt, P. Verzaal, R. van Os, Y. van Kooyk, C. G. Figdor, E.-J. F. M. de Kruijf, R. Willemze, and W. E. Fibbe
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1
Blood,
June 17, 2002;
100(1):
327 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Huang, Z. Chen, J. F. Yu, D. Young, A. Bashey, A. D. Ho, and P. Law
Correlation Between IL-3 Receptor Expression and Growth Potential of Human CD34+ Hematopoietic Cells from Different Tissues
Stem Cells,
September 1, 1999;
17(5):
265 - 272.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. L. Miller, E. L. Korn, D. S. Stevens, J. E. Janik, B. L. Gause, W. C. Kopp, J. T. Holmlund, B. D. Curti, M. Sznol, J. W. Smith II, et al.
Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin
Blood,
May 15, 1999;
93(10):
3250 - 3258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ballestrero, F. Ferrando, A. Garuti, P. Basta, R. Gonella, P. Stura, G. S. Mela, M. Sessarego, M. Gobbi, and F. Patrone
Comparative Effects of Three Cytokine Regimens After High-Dose Cyclophosphamide: Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and Sequential Interleukin-3 and GM-CSF
J. Clin. Oncol.,
April 1, 1999;
17(4):
1296 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F.M. Pruijt, Y. van Kooyk, C. G. Figdor, I. J.D. Lindley, R. Willemze, and W. E. Fibbe
Anti-LFA-1 Blocking Antibodies Prevent Mobilization of Hematopoietic Progenitor Cells Induced by Interleukin-8
Blood,
June 1, 1998;
91(11):
4099 - 4105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eder, G. Geissler, and A. Ganser
IL-3 in the Clinic
Stem Cells,
September 1, 1997;
15(5):
327 - 333.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Lefebvre, J.N. Winter, A.W. Rademaker, C. Goolsby, and I. Cohen
In Vitro Production of Megakaryocytes from PIXY321 versus GM-CSF-Mobilized Peripheral Blood Progenitor Cells
Stem Cells,
March 1, 1997;
15(2):
112 - 118.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Sigounas, M. Steiner, A. Anagnostou, and G. Sigounas
Synergism of Hemopoietic Growth Factors on Endothelial Cell Proliferation
Angiology,
February 1, 1997;
48(2):
141 - 147.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Birkmann, S. Oez, M. Smetak, G. Kaiser, H. Kappauf, and W. M. Gallmeier
Effects of Recombinant Human Thrombopoietin Alone and in Combination with Erythropoietin and Early-Acting Cytokines on Human Mobilized Purified CD34+ Progenitor Cells Cultured in Serum-Depleted Medium
Stem Cells,
January 1, 1997;
15(1):
18 - 32.
[Abstract]
[Full Text]
|
|
|
|
|
